Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
SCTX · Why this verdict
Why Scribe Therapeutics (SCTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Per-dimension breakdown
Quality
1.6/10data confidence 57%| Component | Sub-score |
|---|---|
| Net margin | 0.0 |
| Current ratio | 2.6 |
| Moat | 3.8 |
| Piotroski F | 0.0 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 0/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.9 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 6.5 |
| Volume | 1.0 |
- ▸Volume distribution (falling OBV)
Sentiment
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.3 |
| Analyst rating | 7.1 |
| Price target | 10.0 |
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 99%
Insider
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider buying — $56,344,746 (10.381% of mkt cap)
- ▸Institutions accumulating
Peer rank
2.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.7 |
| quality rank | 0.0 |
| growth rank | 0.6 |
Technical
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.8 |
| support resistance | 5.3 |
| 52w position | 4.5 |
| gap | 6.0 |
Risk (lower is worse)
5.0/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 10.0 |
| volatility | 0.0 |
| news risk | 5.0 |
Catalyst
8.0/10data confidence 25%| Component | Sub-score |
|---|---|
| news activity | 8.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- ASYMMETRY:4.6>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.70
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:2.5<4.5
Warning (0)
none
Reward-to-Risk
4.60
Upside
+69.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.5<4.5 outcome against Insider at 8.5 and asymmetric R:R of 4.60.
The strongest dimensions are Insider at 8.5, Catalyst at 8.0, and Sentiment at 7.7; the weakest are Quality at 1.6, Peer rank at 2.3, and Momentum at 2.5. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 4.60 and an engine sizing output of AVOID.